Preoperative Cisplatin in Early Stage Breast Cancer
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects the preoperative therapy cisplatin will
have on patients with early stage estrogen receptor-negative (ER-), progesterone
receptor-negative (PR-), or HER-2 negative breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Breast Cancer Research Foundation Brigham and Women's Hospital Massachusetts General Hospital